- Daiichi Sankyo‘s operating income for Q1 is 92.98 billion yen.
- This is more than double the 44.03 billion yen from last year.
- Analysts had estimated 57.83 billion yen.
- Net income reached 85.38 billion yen in Q1.
- This is a 50% increase from the previous year.
- It surpassed the estimate of 49.48 billion yen.
- Net sales were 436.18 billion yen for Q1.
- This represents a 24% increase year-over-year.
- Analysts had estimated 407.49 billion yen.
- Daiichi Sankyo has maintained its 2025 year forecast.
- Operating income is forecasted at 230.00 billion yen, below the estimate of 240.02 billion yen.
- Net income is projected at 190.00 billion yen, compared to the estimate of 204.89 billion yen.
- Net sales are expected to be 1.75 trillion yen, slightly below the 1.8 trillion yen estimate.
- The dividend is set at 60.00 yen, above the estimate of 58.64 yen.
- Daiichi Sankyo has 16 buy ratings, 2 hold ratings, and no sell ratings from analysts.
Daiichi Sankyo on Smartkarma
Independent analysts on Smartkarma are optimistic about Daiichi Sankyo‘s future. Avien Pillay‘s report highlighted the company’s strategic focus on oncology and a promising partnership with Merck. Despite the positive outlook, valuation remains a concern for investors. In a separate report by Tina Banerjee, Daiichi Sankyo‘s strong Q4 performance in FY24 exceeded expectations, with significant growth in revenue and operating profit. The company also provided optimistic guidance for FY25, expecting further revenue and profit growth, alongside a planned buyback of shares.
In another insightful report by Tina Banerjee, Daiichi Sankyo raised its revenue and profit forecasts for FY24 and anticipates key FDA approvals for new drugs in FY25. This positive momentum reflects the company’s commitment to innovation and expansion in the pharmaceutical sector. Overall, analysts on Smartkarma remain bullish on Daiichi Sankyo‘s potential, recognizing its advancements in oncology and strategic financial planning for continued growth.
A look at Daiichi Sankyo Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 5 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on the Smartkarma Smart Scores, Daiichi Sankyo shows a promising long-term outlook. With high scores in Growth and Momentum, the company appears to be positioned for strong future performance. The company’s focus on innovation and expansion, as reflected in its Growth score, suggests potential for sustainable growth in the pharmaceutical sector. Additionally, the strong Momentum score indicates positive market sentiment and potential for upward stock price movement.
Daiichi Sankyo‘s Resilience score of 4 further enhances its outlook, indicating the company’s ability to withstand market fluctuations and uncertainties. Although the Value and Dividend scores are not as high, the company’s overall outlook remains positive due to its strengths in Growth, Momentum, and Resilience. With a diverse product portfolio and global reach, Daiichi Sankyo is poised to navigate challenges and capitalize on opportunities in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
